Halozyme Therapeutics HALO Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 83.6%-0.7pp | 84.3%+7.5pp | 76.8%-2.1pp | 78.9%-2.7pp | |
| Efficiency | |||||
| Asset turnover | 0.6×+0.1× | 0.5×+0.1× | 0.5×0.0× | 0.4×-0.1× | |
| Liquidity | |||||
| Current ratio | 4.7×-3.1× | 7.8×+1.2× | 6.6×+1.0× | 5.7×-2.3× | |
| Leverage | |||||
| Debt-to-equity | 44.6×+40.4× | 4.2×-14.1× | 18.3×+9.2× | 9.1×+4.6× | |
| Per Share | |||||
| Book value per share | $0.39-86.0% | $2.81+350% | $0.62-48.3% | $1.21-10.0% | |
| Valuation | |||||
| Market capitalization | $7.91B+30.1% | $6.08B+27.5% | $4.77B-38.0% | $7.7B+39.1% | |
| Price / sales | 5.7×-0.3× | 6×+0.2× | 5.8×-5.9× | 11.7×-0.8× | |
| Price / book | 162.1×+145× | 16.7×-40.2× | 56.9×+11.6× | 45.3×+17.2× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Halozyme Therapeutics's profit margins?
- Halozyme Therapeutics (HALO) runs a 82.8% gross margin and a 59.3% operating margin, with a 47.9% net margin.
- Where do Halozyme Therapeutics's ratios come from?
- Every ratio is computed from Halozyme Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
